Assignee
ACERTA PHARMA BV
NL·21 granted patents·35 pending applications·67 citations·filing 2013–2025
Top patents by PatentIndex Score
56 records- 0196US11771696B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2021·Granted Oct 3, 2023·5 cites·12 claims
- 0295US9949971B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 24, 2018·11 cites·26 claims
- 0394US11654143B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2021·Granted May 23, 2023·3 cites·21 claims
- 0493US10272083B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 30, 2019·14 cites·20 claims
- 0593US9796721B2Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2016·Granted Oct 24, 2017·12 cites·17 claims
- 0691US11090302B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2019·Granted Aug 17, 2021·4 cites·10 claims
- 0788US9522917B2Bruton's tyrosine kinase inhibitors for hematopoietic mobilizationACERTA PHARMA BV·Filed 2013·Granted Dec 20, 2016·6 cites·22 claims
- 0886US12263164B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 0984US10328080B2Therapeutic combination of PI3K inhibitor and a BTK inhibitorACERTA PHARMA BV·Filed 2014·Granted Jun 25, 2019·6 cites·15 claims
- 1084US2024216380A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 1182US2025090525A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2024·Application pending·0 cites
- 1282US2024199622A1Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 1380US11166951B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2018·Granted Nov 9, 2021·2 cites·18 claims
- 1478US11820777B2Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2022·Granted Nov 21, 2023·0 cites·27 claims
- 1578US10167291B2Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2017·Granted Jan 1, 2019·1 cites·28 claims
- 1677US11110088B2Imidazopyrazine inhibitors of Bruton's tyrosine kinaseACERTA PHARMA BV·Filed 2020·Granted Sep 7, 2021·1 cites·2 claims
- 1773US2021346382A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 1872US12448387B2Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yljimidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamideACERTA PHARMA BV·Filed 2024·Granted Oct 21, 2025·0 cites·31 claims
- 1971US11059829B2Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleateACERTA PHARMA BV·Filed 2020·Granted Jul 13, 2021·0 cites·42 claims
- 2071US10640509B2Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphomaACERTA PHARMA BV·Filed 2018·Granted May 5, 2020·0 cites·20 claims
- 2171US2022177476A1Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 2270US12024520B2Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamideACERTA PHARMA BV·Filed 2019·Granted Jul 2, 2024·1 cites·29 claims
- 2370US2024335431A11-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDSACERTA PHARMA BV·Filed 2024·Application pending·0 cites
- 2469US2021322408A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 2569US2019314369A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 2668US11154554B2Therapeutic combinations of a MEK inhibitor and a BTK inhibitorACERTA PHARMA BV·Filed 2019·Granted Oct 26, 2021·0 cites·4 claims
- 2768US10736893B2Imidazopyrazine inhibitors of Bruton's tyrosine kinaseACERTA PHARMA BV·Filed 2016·Granted Aug 11, 2020·1 cites·2 claims
- 2867US2024197742A1Therapeutic Combinations of a CD19 Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 2966US2019231775A1Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine KinaseACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 3064US2019381044A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 3163US2018193337A1Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine KinaseACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3262US2018369244A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3361US2019209591A1Therapeutic Combinations of a Proteasome Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3460US9937171B2Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinaseACERTA PHARMA BV·Filed 2015·Granted Apr 10, 2018·0 cites·17 claims
- 3559US2018250400A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3658US2018318304A1Methods of Using BTK Inhibitors to Treat DermatosesACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3758US2018207154A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3857US2020069668A1Therapeutic Combinations of an IRAK4 Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 3956US2017231986A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 4056US2025360112A11-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDSACERTA PHARMA BV·Filed 2025·Application pending·0 cites
- 4156US2020069796A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 4255US2017035881A1Therapeutic Combinations of an IRAK4 Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2016·Application pending·0 cites
- 4355US2019008869A1Therapeutic Combinations of an Antifolate and a BTK InhibitorACERTA PHARMA BV·Filed 2017·Application pending·0 cites
- 4454US2017224688A1Methods of Using BTK Inhibitors to Treat DermatosesACERTA PHARMA BV·Filed 2017·Application pending·0 cites
- 4554US2017143712A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2017·Application pending·0 cites
- 4654US2017231995A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 4754US2017071962A1Therapeutic Combinations of a Proteasome Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2016·Application pending·0 cites
- 4854US2019008859A1Therapeutic Combinations of a MEK Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2016·Application pending·0 cites
- 4953US2019374543A1Therapeutic Combinations of an Antifolate and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 5052US2019358235A1Therapeutic Combination of a PI3K Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →